Hong Kong Equity Capital Markets

• Initial public offerings by HighTide Therapeutics, WuXi XDC, Laekna, Cutia Therapeutics, MedSci Healthcare, Biocytogen Pharmaceuticals, Yonghe Medical, CANbridge Pharmaceuticals, MicroTech Medical, Abbisko, Broncus, Kindstar Global, HUTCHMED, Zylox-Tonbridge, CARsgen Therapeutics, New Horizon Health, Antengene, RemeGen, JW Therapeutics, Tigermed, Zai Lab, Ocumension Therapeutics, Akeso, InnoCare Pharma, Venus Medtech, CStone Pharmaceuticals, Innovent Biologics, BeiGene, Ping An Good Doctor and 3SBio

U.S. Equity Capital Markets

• Initial public offerings and follow-on offerings by Adagene, Gracell Biotechnologies, Genetron, I-Mab, Zai Lab, BeiGene, ECMOHO, 9F, Douyu, Cango, Uxin, iClick, Rise Education and Edwards Group

Debt Capital Markets

• Investment-grade and MTN notes offerings by China Oceanwide International Financial Management, China Orient Asset Management, Asia Standard International, JD.com, Baidu, PPL Corporation, CSX Corporation, Kennametal, China Forestry Group, China Petrochemical, Greenland Hong Kong, Republic of Indonesia, China Cinda Asset Management, Pertamina and Bangkok Bank
• High-yield notes offerings by Fantasia, Zhenro Properties Group, West China Cement, KWG Property, Guorui Properties, SOCAM Development, China South City, CIFI, PT Cikarang Listrindo, China SCE Property, Times Property, Redco Properties, Central China Real Estate, Fosun International Limited and Dufry AG
• Consent solicitations and tender offers for SOCAM Development, Times Property, Redco Properties, Country Garden, SOHO China, Central China Real Estate and K. Hovnanian Enterprises